Skip to main content

RIPK2 Antibody - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-76960

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-76960
NBP1-76960-0.025mg

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Rat

Cited:

Human

Predicted:

Bovine (95%). Backed by our 100% Guarantee.

Applications

Validated:

ELISA, Immunocytochemistry/ Immunofluorescence, Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Format

BSA Free

Concentration

1 mg/ml

Product Specifications

Immunogen

Antibody was raised against a peptide corresponding to 20 amino acids near the amino terminus of human RICK. The immunogen is located within the first 50 amino acids of RICK. Amino Acid Squence: PTIPYHKLADLRYLSRGASG

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

59 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for RIPK2 Antibody - BSA Free

Western Blot: RIPK2 AntibodyBSA Free [NBP1-76960]

Western Blot: RIPK2 AntibodyBSA Free [NBP1-76960]

Western Blot: RIPK2 Antibody [NBP1-76960] - Analysis of RIPK2 in (A) HeLa, (B) Ramos and (C) EL4 cell lysate with RIPK2 antibody at 1 ug/mL.
Immunocytochemistry/ Immunofluorescence: RIPK2 Antibody - BSA Free [NBP1-76960]

Immunocytochemistry/ Immunofluorescence: RIPK2 Antibody - BSA Free [NBP1-76960]

Immunocytochemistry/Immunofluorescence: RIPK2 Antibody [NBP1-76960] - K562 cells with RIPK2 antibody at 2.5 ug/mL.
RIPK2 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: RIPK2 Antibody - BSA Free [NBP1-76960] -

Immunocytochemistry/ Immunofluorescence: RIPK2 Antibody - BSA Free [NBP1-76960] - Immunofluorescence of RIPK2 in K562 cells with RIPK2 antibody at 20 ug/mL.

Red: RIPK2 Antibody
Blue: DAPI staining

Applications for RIPK2 Antibody - BSA Free

Application
Recommended Usage

ELISA

1:100-1:2000

Immunocytochemistry/ Immunofluorescence

10-20 ug/mL

Western Blot

1 ug/mL

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: RIPK2/RIP2

Apoptosis is mediated by death domain (DD) and/or caspase recruitment domain (CARD) containing molecules and a caspase family of proteases. DD-containing serine/threonine kinase RIP regulates Fas-induced apoptosis. A novel CARD-containing serine/threonine kinase was recently identified and designated RICK/RIP2/CARDIAK for RIP-like interacting CLARP kinase, receptor interacting protein-2, and CARD-containing ICE associated kinase, respectively. RICK contains an N-terminal kinase catalytic domain and a C-terminal CARD domain. Overexpression of RICK induced apoptosis and activation of NF-kappaB and JNK. RICK interacts with members of the TRAF family, CLARP and caspase-1. Thus, RICK represents a novel kinase that regulates TNF and Fas induced-apoptosis and that is involved in the generation of proinflammatory cytokine IL-1beta. The messenger RNA of RICK is expressed in multiple human tissues.

Long Name

Receptor Interacting Serine/Threonine Kinase 2

Alternate Names

CARD3, GIG30, RICK, RIP-2, RIP2

Gene Symbol

RIPK2

UniProt

Additional RIPK2/RIP2 Products

Product Documents for RIPK2 Antibody - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for RIPK2 Antibody - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...